<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182375</url>
  </required_header>
  <id_info>
    <org_study_id>1220.9</org_study_id>
    <nct_id>NCT02182375</nct_id>
  </id_info>
  <brief_title>Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers</brief_title>
  <official_title>An Open Label Fixed Sequence Phase I Study to Investigate the Effect of BI 201335 Mediated UGT1A1 Inhibition on the Multiple Oral Dose Pharmacokinetics of Raltegravir (Isentress®) in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effect of UGT1A1 inhibition by single and multiple oral doses of BI
      201335 on the single and multiple oral dose pharmacokinetics of raltegravir and to
      investigate safety and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state Cmax,ss (maximum measured concentration) of raltegravir and raltegravir glucuronide</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state AUC0-12h,ss (Area under the concentration-time curve) of raltegravir and raltegravir glucuronide</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C12h,ss of raltegravir and raltegravir glucuronide</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Baseline and within 7-14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Baseline and days 1, 5, 6, 7, 15 and within 7-14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 7 - 14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)</measure>
    <time_frame>Baseline, days 1, 5, 6, 7, 15 and within 7-14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory tests (hematology, clinical chemistry, urine analysis)</measure>
    <time_frame>Baseline, days 1, 2, 5, 6, 7, 8, 10, 12, 14, 15, 16 and within 7-14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>within 7-14 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C12h,ss of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12,ss of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (Time from dosing to the maximum measured concentration) of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F0-12,ss (Total apparent clearance) of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F0-12,ss (Apparent volume of distribution) of BI 201335 ZW</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss of raltegravir and raltegravir glucuronide</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F0-12,ss of raltegravir</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F0-12,ss of raltegravir</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of raltegravir and raltegravir glucuronide</measure>
    <time_frame>Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on day 5, 7 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae (Amount of analyte eliminated in urine) of raltegravir and raltegravir glucuronide</measure>
    <time_frame>pre-dose and 0-4, 4-8, 8-12 hours post-dose on day 5, 7, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR (Renal clearance) of raltegravir and raltegravir glucuronide</measure>
    <time_frame>pre-dose and 0-4, 4-8, 8-12 hours post-dose on day 5, 7, 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe (Fraction of analyte eliminated in urine) of raltegravir and raltegravir glucuronide</measure>
    <time_frame>pre-dose and 0-4, 4-8, 8-12 hours post-dose on day 5, 7, 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 201335 NA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg raltegravir (bid) from day 1-14 and once on day 15;
240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335 NA</intervention_name>
    <arm_group_label>BI 201335 NA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <arm_group_label>BI 201335 NA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females

          -  Age ranging ≥ 21 and ≤ 50 years

          -  Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2

          -  Willing to complete all study-related activities including genotyping

          -  Volunteers give their written informed consent prior to admission to the study

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG
             (Electrocardiogram)) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders, clinically relevant electrolyte disturbances

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of photosensitivity or recurrent rash

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or clinically relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24:00 hours) within at least one month or
             less than ten half-lives of the respective drug before enrolment in the study or
             during the study (with the exception of hormonal contraceptives)

          -  Use of any drugs which might influence the results of the trial up to 7 days prior to
             enrolment in the trial or during the trial

          -  Participation in another trial with an investigational drug (within two months prior
             to administration or during the trial)

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars of &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation (&gt; 100 mL within four weeks prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range if indicative of underlying disease
             or poor health

          -  Excessive physical activities within the last week before the trial or during the
             trial

          -  Hypersensitivity to treatment medication and/or related drugs of these classes

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTcF, or QTcB interval &gt;450 ms)

          -  Vulnerable subjects (that is persons kept in detention)

          -  The subject is not able to understand and comply with protocol requirements,
             instructions and protocol-stated restrictions

          -  For Female Subjects:

               -  Pregnancy

               -  Positive pregnancy test

               -  Lactation period

               -  No adequate contraception: females participating in the study must be either (1)
                  of non-childbearing potential (e.g. surgically sterilized or postmenopausal with
                  no menstrual bleeding for at least 2 years prior the study), or (2) using one of
                  the following contraceptive methods plus condom during the course of the study
                  and up to one month (i.e. one complete menstrual cycle) after the last
                  administration of the study drug (whichever is longer): implants of
                  levonorgestrel or injectable progestogen, oral contraceptive - combined or
                  progestogen only, intrauterine device (IUD)- any IUD with published data showing
                  that the lowest expected failure rate is less than 1% per year (not all IUDs meet
                  this criteria)

          -  For Male Subjects:

               -  No adequate contraception: (1) surgically sterilized or (2) or use a condom plus
                  another form of contraception (e.g. spermicide, IUD, birth control pills taken by
                  female partner, diaphragm with spermicide). Male subjects must not father a child
                  from administration of the first dose and up to 3 months after the last dose of
                  study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

